Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  GlaxoSmithKline    GSK   GB0009252882

GLAXOSMITHKLINE (GSK)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Australian watchdog takes GlaxoSmithKline, Novartis units to court

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/06/2017 | 12:26am CET
Swiss drugmaker Novartis' logo is seen in Stein

The Australian Competition and Consumer Commission (ACCC) on Wednesday said it is taking local units of GlaxoSmithKline (>> GlaxoSmithKline) and Swiss healthcare company Novartis (>> Novartis) to court over false or misleading representations in the marketing of pain relief products.

The Australian Competition and Consumer Commission (ACCC) on Wednesday said it is taking local units of GlaxoSmithKline (>> GlaxoSmithKline) and Swiss healthcare company Novartis (>> Novartis) to court over false or misleading representations in the marketing of pain relief products.

The ACCC alleged that the companies tried to market their two pain relief products, Osteo Gel and Emulgel, as having different levels of impact in treating osteoarthritis, when in fact they are "identically formulated".

"We allege that consumers are likely to have been misled into purchasing Osteo Gel thinking that it is different to Emulgel and more effective for treating osteoarthritis conditions, when this is not the case”, ACCC Chairman Rod Sims said.

ACCC's concerns come as a price sampling conducted by it noted that supermarkets and pharmacies often sold Osteo Gel at a significant price premium to Emulgel.

The regulator is seeking declarations, injunctions, pecuniary penalties, and a publication order in relation to its allegations.

"The alleged conduct is particularly concerning, given the significant penalties handed down by the court against the makers of Nurofen for what we consider to be similar conduct,” Sims said.

In December last year, the Federal court of Australia upheld an appeal by the regulator against Reckitt Benckiser's (>> Reckitt Benckiser) Australian unit for similar charges on its Nurofen Specific Pain products, imposing a A$6 million (£3.40 million) penalty.

(Reporting by Susan Mathew in Bengaluru; Editing by Stephen Coates)

Stocks treated in this article : Novartis, Reckitt Benckiser, GlaxoSmithKline
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GLAXOSMITHKLINE
11:19a SANOFI : A faster method for harvesting HSCs for transplantation
12/08 GLAXOSMITHKLINE : New data supports the safety and efficacy of GSK's Shingrix in..
12/07 GLAXOSMITHKLINE : New Findings in Medical Statistics Described from GlaxoSmithKl..
12/07 REPORTS OUTLINE PHARMACEUTICAL RESEA : Role of biomarker...
12/07 U.K. unveils life sciences sector deal
12/07 Companies prepare for disorderly Brexit as talks stall
12/06 GSK, other drugmakers bet on post-Brexit UK science
12/06 GLAXOSMITHKLINE : New data supports the safety and efficacy of GSK’s Shing..
12/06 GLAXOSMITHKLINE : GSK welcomes launch of the UK Government’s Life Sciences..
12/06 GLAXOSMITHKLINE : New data - Shingrix in immune-compromised patients
More news
News from SeekingAlpha
12/08 FDA tentatively OKs Impax Labs' generic Coreg CR
12/07 YOUR DAILY PHARMA SCOOP : Gilead's Potential, Celgene CAR-T Candidate, Cellectar..
12/06 Glaxo's Shingrix shows treatment benefit in late-stage study in HSCT patients
12/06 WALL STREET BREAKFAST : Holy Sell-Off Hits The Markets
12/06 Australia takes GSK, Novartis to court
Financials ( GBP)
Sales 2017 30 089 M
EBIT 2017 8 245 M
Net income 2017 3 652 M
Debt 2017 14 293 M
Yield 2017 6,21%
P/E ratio 2017 18,03
P/E ratio 2018 14,60
EV / Sales 2017 2,58x
EV / Sales 2018 2,54x
Capitalization 63 328 M
Chart GLAXOSMITHKLINE
Duration : Period :
GlaxoSmithKline Technical Analysis Chart | GSK | GB0009252882 | 4-Traders
Technical analysis trends GLAXOSMITHKLINE
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 32
Average target price 15,5  GBP
Spread / Average Target 20%
EPS Revisions
Managers
NameTitle
Emma Walmsley Chief Executive Officer & Executive Director
Philip Roy Hampton Non-Executive Chairman
Simon Dingemans Chief Financial Officer & Executive Director
Patrick J. T. Vallance Executive Director, President-R&D
Karenann K. Terrell Chief Technology Officer
Sector and Competitors
1st jan.Capitalization (M$)
GLAXOSMITHKLINE-18.34%84 764
JOHNSON & JOHNSON21.23%377 698
NOVARTIS11.34%218 728
PFIZER9.48%213 036
ROCHE HOLDING LTD.6.19%208 877
MERCK AND COMPANY-7.68%151 559